Insmed Incorporated (LON:0JAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 14.49B |
| Revenue (ttm) | 294.91M |
| Net Income (ttm) | -784.26M |
| Shares Out | n/a |
| EPS (ttm) | -4.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197 |
| Average Volume | 549 |
| Open | 105.50 |
| Previous Close | 103.07 |
| Day's Range | 103.19 - 105.50 |
| 52-Week Range | 61.28 - 106.50 |
| Beta | 0.79 |
| RSI | 68.82 |
| Earnings Date | Aug 7, 2025 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]
Financial Performance
In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.
Financial numbers in USD Financial StatementsNews
Lightning Round: When it comes to AI, I believe in Nvidia, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Insmed, Ouster, First Silver Corp, FMC, and Tempus AI.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Insmed (NASDAQ: INSM) has outperformed the market over the past 10 years by 3.38% on an annualized basis producing an average annual return of 14.93%. Currently, Insmed has a market capitalization of...
What Does the Market Think About Insmed?
Insmed's (NYSE: INSM) short percent of float has risen 5.99% since its last report. The company recently reported that it has 17.46 million shares sold short , which is 10.8% of all regular shares th...
Is Insmed Stock Overvalued After The 45% Jump?
Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?
Insmed prices capital raise of $750 via stock offering
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ: INSM) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently, Insmed has a market capitalization of...
Insmed announces $650M public offering of common stock
Insmed Announces Proposed $650 Million Public Offering of Common Stock
BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...
Liquidia: Competitor Insmed's Stunning PAH Data Arrives At Precisely The Wrong Time
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
Insmed Incorporated (NASDAQ: INSM) on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary ar...
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hype...
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Needham r...
Insmed CEO Will Lewis on stock surge after positive trial results
Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.
Insmed CEO Will Lewis on stock surge after positive trial results
Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.
3 Stocks With The 'Insider Advantage'
There’s a well-worn line in value investing circles that says, “I want to invest with people who eat their own cooking.” In other words, you want the people running the company to have a meaningful ch...
Insmed: Company Presses On With Further POC PAH Treatment Data
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2194283558-06b4eff0af2b4cc892d742e8db0c10af.jpg)
Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results
Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension.
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday. The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S...
Caseys Enjoys 'Good Quarter,' Analyst Praises Steady Fuel Volumes
Stephens analyst Pooran Sharma reiterated the Overweight rating on Caseys General Stores, Inc. (NASDAQ: CASY), with a price forecast of $490. On June 9, the company reported fourth-quarter financial ...
Stocks making the biggest moves midday: Topgolf Callaway, Insmed, J.M. Smucker, SolarEdge & more
These are the stocks posting the largest moves midday.
Liquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH asset
Insmed's blood pressure drug meets main goal in mid-stage trial
Insmed said on Tuesday that its experimental blood pressure drug met the main goals in a mid-stage study.
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
–The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p